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The PTEN gene is involved in 10q23 deletions in several types of cancer, including glioma, melanoma, endometrial and prostate
carcinomas. The PTEN gene product is a dual-specificity phosphatase with putative tumor suppressor function. Deletions and
rearrangements of 10q22–25 have been reported in ,5%–10% of non-Hodgkin’s lymphomas (NHLs), raising the possibility of
PTEN involvement in these tumors. In order to address this question, we analyzed a panel of NHLs (n 5 74) representative of
the main histologic subtypes for mutations and homozygous deletions of PTEN. We report somatic coding/splice site mutations
in 20% (2 of 10) of Burkitt’s lymphoma cell lines and in 3% (2 of 64) of primary NHL cases analyzed. No homozygous deletions
were found in these tumors. Interestingly, this study showed that cytogenetically characterized NHL cases (n 5 6) with
10q22–q25 abnormalities displayed neither biallelic deletions nor mutations of PTEN. These results suggest that a tumor
suppressor gene distinct from PTEN may be involved in 10q deletions in this subgroup of NHL cases. Genes Chromosomes Cancer
24:322–327, 1999. r 1999 Wiley-Liss, Inc.
INTRODUCTION
Non-Hodgkin’s lymphoma (NHL), the fifth most
common human malignancy, is most often of B-cell
origin and is characterized by marked biological and
clinical heterogeneity. The pathogenesis of this
tumor is associated with chromosomal transloca-
tions that lead to the deregulated expression of
various proto-oncogenes found at the breakpoint
junction area by their juxtaposition to regulatory
elements of genes, most often the immunoglobulin
genes (Gaidano and Dalla-Favera, 1997).
Relatively less is known about the involvement
of tumor suppressor genes (TSGs) in NHL patho-
genesis. Genetic alterations of TP53 have been
reported in 20% of diffuse large-cell lymphoma and
in 30% of Burkitt’s lymphoma cases, respectively
(Gaidano et al., 1991; LoCoco et al., 1993; Ichikawa
et al., 1997). Alterations have also been described in
p16INK4A principally occurring in mantle cell lympho-
mas, an uncommon lymphoma subtype (Cohen et
al., 1997). Karyotypic analysis has revealed recur-
rent deletions at 10q22–25, suggesting that this
chromosomal locus may harbor a tumor suppressor
gene relevant to B-cell lymphomagenesis (Offit et
al., 1991; Speaks et al., 1992).
Recently, a putative tumor suppressor gene,
PTEN (for phosphatase and tensin homologue,
located on chromosome 10) was identified based on
its involvement in 10q23 deletions in a variety of
solid tumors (Li et al., 1997; Steck et al., 1997). The
gene was found to be mutated or homozygously
deleted in glial, prostate, endometrial, kidney, tes-
tis, and breast cancers as well as in leukemia and
melanoma (Guldberg et al., 1997; Rhei et al., 1997;
Tashiro et al., 1997; Teng et al., 1997; Wang et al.,
1997). In addition, germline mutations of PTEN
have been found in a group of inherited predisposi-
tion cancer syndromes, including Cowden disease
and Bannayan-Zonona syndrome (Liaw et al., 1997;
Marsh et al., 1997). PTEN encodes for a ubiqui-
tously expressed cytoplasmic tyrosine phosphatase,
which contains a region of homology to tensin and
auxilin, which are known as cytoskeletal proteins
(Li et al., 1997).
To determine if the target of 10q anomalies in
NHL (Offit et al, 1991; Speaks et al, 1992) involve
the PTEN gene, we analyzed a panel of NHL
biopsies and cell lines for mutations and deletions
within the coding and exon-intron boundary do-
mains of this putative TSG.
M.P.B. was supported by the Mater College Hospital, Dublin, and
the Vocational Education Committee, Co. Donegal, Ireland, and is a
registered Ph.D. student from the University College Dublin,
Ireland.
Supported by: National Institutes of Health; Grant number:
CA-44029.
*Correspondence to: Dr. Riccardo Dalla-Favera, Division of
Oncology, Department of Pathology, College of Physicians and
Surgeons, Columbia University, 630 West 168th Street, New York,
NY 10032.
Received 7 July 1998; Accepted 24 September 1998
GENES, CHROMOSOMES & CANCER 24:322–327 (1999)
r 1999 Wiley-Liss, Inc.
MATERIALS AND METHODS
Tumor Biopsies and Cell Lines
Sixty-four tumor biopsies from NHL patients
were used for PTEN mutational analysis. The NHL
panel was representative of the major B-cell NHL
categories (Table 1). Ten Burkitt’s lymphoma cell
lines were also included. The karyotypic and immu-
nophenotypic characterization of these cell lines
has been reported previously (Lenoir et al., 1982;
Parsa et al., 1994).
Mutation Analysis
Amplification of exons 1 to 9 of PTEN from
normal/tumor DNA was achieved through the use
of intron-based primers reported previously (Wang
et al., 1997). PCR amplification was performed in a
25-µl reaction volume using 100 ng of genomic
DNA, 1.5–2.0-mM MgCl2, 100 µM each dNTP,
0.5-–M primer and 0.5-U Taq DNA polymerase
(AmpliTaq, Perkin-Elmer, Foster City, CA). The
cycling parameters were as follows: initial denatur-
ation step at 94°C for 5 min, followed by 30 rounds
of thermal cycling at 94°C for 30 sec, 56°C for 30
sec, 72°C for 30 sec, with a final extension period
of 72°C for 5 min using a Perkin-Elmer Cetus 9600
GeneAmp PCR system; a different annealing
temperature (58°C) was used for exon 4. PCR
products were purified on columns (Wizard PCR
Preps DNA purification system, Promega, Madi-
son, WI) prior to sequencing by the dideoxy chain
termination method using an automated sequenc-
ing system, ABI 373 (Applied Biosystems, Foster
City, CA). Sequencing primers were the same as
those used to amplify tumor DNA except for
the following: exon 1 reverse 5’-ACGTTC-
TAAGAGAGTGACAGA-3’; exon 5 forward 5’-
ATTCTGAGGTTATCTTTTTACC-3’; exon 8
forward 5’-GTAAATACATTCATACCAG -3’; exon
9 forward 5’-TCTCTAGGTGAAGCTGTACT-3’.
All cases with mutations were analyzed twice to
ensure reproducibility. To characterize the deletion
mutations, PCR products were subcloned into the
pGEM-T plasmid (Promega) and sequenced.
Homozygous Deletion Assessment
Biallelic deletions of PTEN were analyzed by
Southern blot analysis using high-molecular-weight
DNA available for 38 of the same 64 primary NHL
cases used for sequence analysis. Briefly, 10 µg of
tumor and normal tonsil DNA were digested with
EcoRI and EcoRV restriction enzymes, run on 0.8%
agarose gels, transferred to nitrocellulose mem-
branes, and hybridized with probes specific for each
PTEN coding exon. These probes were prepared
from normal human DNA by PCR using the same
primers used to amplify the tumor DNA for direct
sequence analysis. All the PCR products were
gel-purified followed by purification on columns
(Wizard PCR purification system, Promega). Exon
probes were first tested individually on EcoRI and
EcoRV Southern blot filters prepared from normal
tonsil DNA to determine the specific banding
pattern given by each individual exon. Next, pools
of the nine PCR-derived PTEN exon probes
(Fig. 1) were used to screen NHL Southern blot
filters. The signal intensity given by all probes was
measured using a PhosphorImager (Molecular Dy-
namics, Sunnyvale, CA) and normalized to the
signal of a reference probe (exon 9 of the BCL-6
gene, which has no deletions in NHL) (Gaidano
and Dalla-Favera, 1997). When using exon probes
5, 6, 7, 8, and 9, two or three bands were seen on
Southern blot, which were found to represent
PTEN homologous sequences. The identification
of the PTEN-specific band in such cases was
achieved by the hybridization of these exon probes
to somatic cell hybrid Southern blot filters (full
panel of 24 chromosomes), which were digested
with EcoRI and EcoRV restriction enzymes (Map-
ping Panel #2, NIGMS Human Genetic Mutant
Cell Repository, Coriell Institute for Medical Re-
search, Camden, NJ) (data not shown). By this
approach we could show that each band seen on
Southern blot (Fig. 1) corresponded to a single
chromosomal locus (data not shown). The signals
corresponding to the PTEN gene as well as the
pseudogene (chromosome 9) (Teng et al., 1997) are
both indicated in cases where an exon probe gives
rise to two or more bands on Southern blot. The
signal intensity of the PTEN-specific bands was
measured and a .60% reduction in tumor versus
TABLE 1. Frequency of PTEN Mutation/Deletion in NHL
NHL subtypea Mutations
Homozygous
deletions
SML 1/5 0/5
LPL 0/7 0/2
MCL 0/5 0/3
FCL 0/20 0/18
DLCL 1/27 0/10
BL 2/10 0/10
Total 4/74 0/48
aNHL subtype: SML, small lymphocytic lymphoma; LPL, lymphoplasmacy-
toid lymphoma; MCL, mantle cell lymphoma; FCL, follicular center-cell
lymphoma; DLCL, diffuse large-cell lymphoma; BL, Burkitt’s lymphoma
(cell lines).
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Figure 1. Homozygous deletion assessment of PTEN in representa-
tive NHL cases. A–C: Southern blots of DNAs digested with EcoRV.
D–F: Southern blots using EcoRI. Sizes given by molecular weight
marker are indicated in A and D. The bands produced by the exon
probes are indicated by the arrows. A represents the hybridization of
PTEN exons 2, 5, 6, and 9; B, that of exons 3 and 4; D, E, and F, that of
exon probes 1, 7, and 8, respectively. The reference probe used was
exon 9 of BCL-6, which is located at chromosomal locus 3q27 (see C and
D). Exon probes producing two or more bands (exons 5, 6, 7, 8, and 9)
represent cross-hybridization to the PTEN pseudogene (chromosome 9;
represented by c), as well as to sequences located on additional
chromosomes, which may represent PTEN homologues (data not
shown). The first lane is normal tonsil DNA; lanes 1–3 are representa-
tive follicular center-cell lymphoma cases; lanes 4–6 are Burkitt’s
lymphoma cell lines.
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normal DNA was interpreted as evidence of bialle-
lic deletion (normal contaminating DNA is present
in NHL biopsies).
RESULTS
PTEN Mutation Analysis
The entire coding domain of PTEN, including
splice site junction regions, was examined for
sequence variations in a total of 64 NHL cases and
in 10 cell lines. The NHL panel used to investigate
PTEN mutational inactivation is given in Table 1
and is representative of the major B-cell NHL
histological subtypes. Systematic scanning of all
nine exons of PTEN led to the identification of
coding/splice site mutations in 2 of 10 (20%) Bur-
kitt’s lymphoma cell lines, and in 2 of 64 (3%)
primary NHL cases (Table 2). No mutations or
biallelic deletions were observed in the NHL cases
karyotypically defined as having 10q abnormalities
(Table 3).
The mutations detected in the Burkitt’s lym-
phoma cell lines were of somatic origin as they were
not found in their normal DNA counterparts
(Fig. 2, Table 2). Among these alterations, a mis-
sense mutation was detected in BL30, an A-to-T
transversion resulting in a histidine-to-leucine
change at codon 61. The other allele was deleted in
this cell line. A second BL cell line, BL108, carried
a nonsense mutation, a C-to-T transition at codon
335, and retained a normal second allele.
Among primary NHL cases, a small lymphocytic
lymphoma case (case no. 857; Table 2) displayed a
4-bp deletion located 1 bp 5’ to the acceptor splice
site of exon 4. In addition, a diffuse large B-cell
lymphoma (case no. 1687) carried a silent mutation,
a G-to-A transition, at codon 307 within exon 8.
Other sequence variants were found in two lympho-
mas displaying intronic base pair substitutions, in
intron 1 (case no. 1335) and in intron 8 (case no.
1494). In all primary cases, a second wild-type allele
was detectable, but we could not determine whether
it was present in tumor cells or in contaminating
normal cells. Finally, a recurrent missense mutation
located 32 bp 3’ to the splice donor site of exon 8
[TTG(T/G)TGACT] was detectable in multiple
cases. This mutation was previously described in
other individuals (Wang et al., 1997), suggesting
that it may represent a germline population polymor-
phism.
Deletion Assessment of PTEN
Homozygous deletions of PTEN were studied by
Southern blot analysis using probes specific for
each of the nine exons of PTEN. Through the use
of two restriction enzymes, it was possible to
identify an exon-specific banding pattern (Fig. 1),
thus allowing for the detection of deletions of
individual exons. No biallelic deletion of PTEN was
detectable among 38 primary NHL cases. Monoal-
lelic loss could not be reliably assessed due to the
presence of normal DNA contaminating the
samples.
DISCUSSION
Mutations and deletions of the PTEN gene on
10q23 are emerging as a common genetic alteration
in a variety of sporadic human cancer types as well
as in some hereditary tumor predisposition syn-
TABLE 2. PTEN Mutations in NHL
Case
NHL
subtypea
Exon/
intron Codonb Mutation
Predicted
effect Allelic status
BL30 BL Exon 3 61 A182T His . Leu Homozygous
BL108 BL Exon 8 335 C1003T Arg . Stop Heterozygous
857 SML Intron 3 Splice site 210-3delCTTT Splicing variant Heterozygous
1687 DLCL Exon 8 307 G921A Glu . Glu Heterozygous
1494 FCL Intron 8 NA 1026 1 43 G . A – Heterozygous
1335 MCL Intron 1 NA 79 1 11 C . T – Heterozygous
aNHL subtype: BL, Burkitt’s lymphoma (cell line); SML, small lymphocytic lymphoma; DLCL, diffuse large-cell lymphoma; FCL, follicular center-cell
lymphoma; MCL, mantle cell lymphoma.
bNA, not applicable.
TABLE 3. Mutation and Deletion Analysis of PTEN
in NHL Cases With 10q Abnormalities
Case
number
NHL
subtypea Cytogenetics Mutation
Homozygous
deletion
1381 FCL del(10)(q22q24) Negative Negative
1382 DLCL t(4;10)(q31;q24) Negative Not done
1383 FCL del(10)(q22q24) Negative Negative
1384 LPL t(10;14)(q24;q32) Negative Negative
1385 DLCL t(9;10)(q34;q24) Negative Not done
1386 LPL add(10)(q24) Negative Not done
aNHL subtype: FCL, follicular center-cell lymphoma; LPL, lymphoplasma-
cytoid lymphoma; DLCL, diffuse large-cell lymphoma.
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dromes. Based on the presence of chromosome
10q22–25 deletions and rearrangements in ,5%–
10% of NHLs (Offit et al., 1991; Speaks et al.,
1997), this study was aimed at assessing whether
PTEN was involved in these cytogenetic abnormali-
ties. Our results show that alterations of the coding
region of PTEN are not common in NHL and have
implications for the understanding of the signifi-
cance of 10q deletions in these malignancies.
In this study, we detected mutations of the
PTEN gene in 20% (2 of 10) of the BL cell lines and
in 3% (2 of 64) of primary NHL cases. Both
mutations detected in the BL cell lines may have
functional significance. The missense mutation
leading to a histidine-to-leucine alteration at codon
61 involves a residue conserved in the homologous
domain, which in cytoskeletal tensin binds to actin
filaments at focal adhesions (Li et al., 1997), suggest-
ing that it may be part of an important regulatory
domain in PTEN. Because the second PTEN allele
was deleted in this cell line, it is conceivable that
PTEN function may be lost in this case. The second
BL cell line carried a nonsense mutation at codon
335, which has been recurrently observed in both
glial and endometrial carcinomas (Risenger et al.,
1997; Wang et al., 1997), suggesting that it may
represent a frequent target for PTEN inactivation.
Finally, a small deletion detected in a small lympho-
cytic lymphoma case near the acceptor splice site
may disrupt the normal splicing of exon 4, leading
to exon skipping and ultimately truncation of the
PTEN protein product.
In one of the BL cell lines (BL108), the mutant
PTEN allele coexisted with the wild-type allele;
also in the small lymphocytic lymphoma the wild
type allele was detectable, although its derivation
from normal versus tumor cells could not be deter-
mined. These findings may represent the ‘‘first hit’’
(Knudson et al., 1971), while mutation/deletion of
the second allele may not yet have occurred.
Alternatively, the second allele may have been
inactivated by mutation in the regulatory region of
the gene or through methylation. Another possibil-
ity is that monoallelic inactivation of PTEN may be
sufficient to produce a biological effect, as has been
suggested for other TSGs (Donehower et al., 1995).
Figure 2. Detection of somatic mutations in Burkitt’s lymphoma cell
lines by direct sequence analysis. A shows the chromatograms of BL30
and its normal counterpart, IARC139: a missense mutation at codon 61
leads to an A-to-T transversion resulting in a histidine to leucine
substitution (CAT to CTT). B gives the chromatogram of BL108 and
corresponding normal DNA, IARC602. A nonsense mutation is de-
tected at codon 335, as a result of a CGA-to-TGA change.
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The availability of anti-PTEN antibodies as well as
the analysis of mice with monoallelic PTEN loss
should allow for these possibilities to be addressed.
The results presented in this study indicate that
cytogenetically detectable alterations of 10q23 are
significantly more frequent in NHL than the occur-
rence of PTEN mutations. Our findings have been
corroborated by a recent report showing infrequent
alterations of PTEN (2 of 14 cell lines and 2 of 170
primary tumors) among lymphoid malignancies
(Gronbaek et al., 1998). The same observation is
valid for thyroid, colon, ovarian, and pancreatic
cancers, which all display 10q23 deletions, but
infrequent PTEN mutations (Dahia et al., 1997;
Tashiro et al., 1997; Teng et al., 1997). Indeed, we
detected no mutations or biallelic deletions of
PTEN in the lymphoma cases with cytogenetically
detectable 10q anomalies included in this study.
Thus, these results may suggest that haploinsuffi-
ciency of PTEN may produce a biological effect in
these diverse tumor types or, alternatively, that
another TSG may be located at 10q that is involved
in these tumors.
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